CDCA4 is aberrantly regulated in various cancers, comprising triple-negative breast cancer (BC), Wilm’s tumour, melanoma, and osteosarcoma, and is associated with poor patient outcomes (13, 25–28). The gene discussed is CDCA4; the disease is triple-negative breast carcinoma.